A detailed history of Intellectus Partners, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Intellectus Partners, LLC holds 1,055 shares of REGN stock, worth $740,451. This represents 0.29% of its overall portfolio holdings.

Number of Shares
1,055
Previous 1,055 -0.0%
Holding current value
$740,451
Previous $1.11 Million 0.09%
% of portfolio
0.29%
Previous 0.31%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 18, 2024

SELL
$883.2 - $1071.19 $88,320 - $107,119
-100 Reduced 8.66%
1,055 $1.11 Million
Q1 2024

May 03, 2024

SELL
$902.69 - $993.35 $112,836 - $124,168
-125 Reduced 9.77%
1,155 $1.11 Million
Q3 2023

Oct 25, 2023

SELL
$692.45 - $844.37 $274,902 - $335,214
-397 Reduced 23.67%
1,280 $1.05 Million
Q2 2023

Jul 31, 2023

SELL
$700.03 - $830.35 $140,006 - $166,070
-200 Reduced 10.66%
1,677 $1.2 Million
Q1 2023

May 04, 2023

BUY
$680.49 - $826.97 $14,970 - $18,193
22 Added 1.19%
1,877 $1.54 Million
Q4 2022

Feb 02, 2023

SELL
$705.89 - $766.39 $29,647 - $32,188
-42 Reduced 2.21%
1,855 $1.34 Million
Q3 2022

Nov 14, 2022

SELL
$573.97 - $724.32 $50,509 - $63,740
-88 Reduced 4.43%
1,897 $1.31 Million
Q1 2022

May 16, 2022

SELL
$595.12 - $698.43 $104,146 - $122,225
-175 Reduced 8.1%
1,985 $1.39 Million
Q4 2021

Feb 14, 2022

SELL
$543.48 - $670.97 $298,914 - $369,033
-550 Reduced 20.3%
2,160 $1.36 Million
Q3 2021

Nov 16, 2021

BUY
$574.03 - $680.96 $123,416 - $146,406
215 Added 8.62%
2,710 $1.64 Million
Q2 2021

Aug 13, 2021

BUY
$472.8 - $558.54 $14,184 - $16,756
30 Added 1.22%
2,495 $1.39 Million
Q1 2021

May 17, 2021

SELL
$446.73 - $548.2 $364,084 - $446,783
-815 Reduced 24.85%
2,465 $1.17 Million
Q4 2020

Feb 18, 2021

BUY
$478.3 - $607.98 $1.42 Million - $1.81 Million
2,971 Added 961.49%
3,280 $1.59 Million
Q4 2020

Feb 12, 2021

SELL
$478.3 - $607.98 $929,336 - $1.18 Million
-1,943 Reduced 86.28%
309 $1.59 Million
Q3 2020

Nov 16, 2020

BUY
$544.75 - $658.21 $423,815 - $512,087
778 Added 52.78%
2,252 $1.26 Million
Q2 2020

Aug 14, 2020

BUY
$493.32 - $643.92 $20,226 - $26,400
41 Added 2.86%
1,474 $919,000
Q1 2020

May 14, 2020

SELL
$336.18 - $494.43 $1.09 Million - $1.6 Million
-3,245 Reduced 69.37%
1,433 $700,000
Q4 2019

Jan 24, 2020

BUY
$274.13 - $376.51 $259,601 - $356,554
947 Added 25.38%
4,678 $1.76 Million
Q3 2019

Oct 11, 2019

BUY
$273.46 - $318.39 $255,138 - $297,057
933 Added 33.35%
3,731 $1.04 Million
Q2 2019

Aug 08, 2019

BUY
$299.6 - $414.82 $138,415 - $191,646
462 Added 19.78%
2,798 $876,000
Q1 2019

May 15, 2019

SELL
$372.08 - $439.57 $52,463 - $61,979
-141 Reduced 5.69%
2,336 $959,000
Q4 2018

Feb 14, 2019

BUY
$335.82 - $403.04 $378,804 - $454,629
1,128 Added 83.62%
2,477 $925,000
Q3 2018

Nov 15, 2018

SELL
$351.14 - $408.51 $314,270 - $365,616
-895 Reduced 39.88%
1,349 $545,000
Q2 2018

Aug 14, 2018

BUY
$284.6 - $344.99 $264,393 - $320,495
929 Added 70.65%
2,244 $774,000
Q1 2018

May 15, 2018

SELL
$315.82 - $393.78 $34,108 - $42,528
-108 Reduced 7.59%
1,315 $453,000
Q3 2017

Nov 14, 2017

SELL
$431.38 - $504.0 $140,629 - $164,304
-326 Reduced 18.64%
1,423 $636,000
Q2 2017

Aug 15, 2017

BUY
N/A
1,749
1,749 $859,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $75.2B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Intellectus Partners, LLC Portfolio

Follow Intellectus Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Intellectus Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Intellectus Partners, LLC with notifications on news.